Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice
et al., Antimicrob. Agents Chemother, August 2009, 53(8), doi:10.1128/AAC.01509-08, Aug 2009
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,200+ studies for
200+ treatments. c19early.org
|
CQ inhibits HCoV-OC43 replication in HRT-18 cells. A lethal HCoV-OC43 infection in newborn C57BL/6 mice can be treated with CQ acquired transplacentally or via maternal milk. The highest survival rate (98.6%) was found when mother mice were treated daily with a concentration of 15 mg of CQ per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg/kg CQ and 13% survival when treated with 1 mg/kg CQ. CQ can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.
39 preclinical studies support the efficacy of HCQ for COVID-19:
1.
Shang et al., Identification of Cathepsin L as the molecular target of hydroxychloroquine with chemical proteomics, Molecular & Cellular Proteomics, doi:10.1016/j.mcpro.2025.101314.
2.
González-Paz et al., Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data, ACS Omega, doi:10.1021/acsomega.3c06968.
3.
Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.
4.
Guimarães Silva et al., Are Non-Structural Proteins From SARS-CoV-2 the Target of Hydroxychloroquine? An in Silico Study, ACTA MEDICA IRANICA, doi:10.18502/acta.v61i2.12533.
5.
Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.
7.
Yadav et al., Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study, Research Square, doi:10.21203/rs.3.rs-628277/v1.
8.
Hussein et al., Molecular Docking Identification for the efficacy of Some Zinc Complexes with Chloroquine and Hydroxychloroquine against Main Protease of COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129979.
9.
Baildya et al., Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891.
10.
Noureddine et al., Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2020.101334.
11.
Tarek et al., Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention, European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-020-00640-6.
12.
Rowland Yeo et al., Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1955.
13.
Hitti et al., Hydroxychloroquine attenuates double-stranded RNA-stimulated hyper-phosphorylation of tristetraprolin/ZFP36 and AU-rich mRNA stabilization, Immunology, doi:10.1111/imm.13835.
14.
Yan et al., Super-resolution imaging reveals the mechanism of endosomal acidification inhibitors against SARS-CoV-2 infection, ChemBioChem, doi:10.1002/cbic.202400404.
15.
Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.
16.
Alsmadi et al., The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel, AAPS PharmSciTech, doi:10.1208/s12249-023-02627-3.
17.
Wen et al., Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells, Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048.
18.
Kamga Kapchoup et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.
19.
Milan Bonotto et al., Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection, Antiviral Research, doi:10.1016/j.antiviral.2023.105655.
20.
Miao et al., SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells, Cell Chemical Biology, doi:10.1016/j.chembiol.2023.02.001.
21.
Yuan et al., Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Communications Biology, doi:10.1038/s42003-022-03841-8.
22.
Faísca et al., Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2, Pharmaceutics, doi:10.3390/pharmaceutics14040877.
23.
Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.
24.
Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia, PLOS One, doi:10.1371/journal.pone.0252302.
25.
Zhang et al., SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination, Cell Death & Differentiation, doi:10.1038/s41418-021-00782-3.
26.
Dang et al., Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein, bioRxiv, doi:10.1101/2021.03.16.435741.
27.
Shang (B) et al., Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice, Virology Journal, doi:10.1186/s12985-021-01515-1.
28.
Wang et al., Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus, Phytomedicine, doi:10.1016/j.phymed.2020.153333.
29.
Sheaff, R., A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity, bioRxiv, doi:10.1101/2020.08.02.232892.
30.
Ou et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLOS Pathogens, doi:10.1371/journal.ppat.1009212.
31.
Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
32.
Clementi et al., Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704.
33.
Liu et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0.
34.
Yao et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237.
Keyaerts et al., 1 Aug 2009, peer-reviewed, 7 authors.
Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01509-08
Until recently, human coronaviruses (HCoVs), such as HCoV strain OC43 (HCoV-OC43), were mainly known to cause 15 to 30% of mild upper respiratory tract infections. In recent years, the identification of new HCoVs, including severe acute respiratory syndrome coronavirus, revealed that HCoVs can be highly pathogenic and can cause more severe upper and lower respiratory tract infections, including bronchiolitis and pneumonia. To date, no specific antiviral drugs to prevent or treat HCoV infections are available. We demonstrate that chloroquine, a widely used drug with well-known antimalarial effects, inhibits HCoV-OC43 replication in HRT-18 cells, with a 50% effective concentration (؎ standard deviation) of 0.306 ؎ 0.0091 M and a 50% cytotoxic concentration (؎ standard deviation) of 419 ؎ 192.5 M, resulting in a selectivity index of 1,369. Further, we investigated whether chloroquine could prevent HCoV-OC43-induced death in newborn mice. Our results show that a lethal HCoV-OC43 infection in newborn C57BL/6 mice can be treated with chloroquine acquired transplacentally or via maternal milk. The highest survival rate (98.6%) of the pups was found when mother mice were treated daily with a concentration of 15 mg of chloroquine per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg/kg chloroquine and 13% survival when treated with 1 mg/kg chloroquine. Our results show that chloroquine can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.
References
Akintonwa, Gbajumo, Mabadeje, Placental and milk transfer of chloroquine in humans, Ther. Drug Monit
Akintonwa, Meyer, Yau, Placental transfer of chloroquine in pregnant rabbits, Res. Commun. Chem. Pathol. Pharmacol
Arbour, Day, Newcombe, Talbot, Neuroinvasion by human respiratory coronaviruses, J. Virol
Arden, Nissen, Sloots, Mackay, New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia, J. Med. Virol
Augustijns, Jongsma, Verbeke, Transplacental distribution of chloroquine in sheep, Dev. Pharmacol. Ther
Barnard, Day, Bailey, Heiner, Montgomery et al., Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice, Antivir. Chem. Chemother
Blau, Holmes, Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway
Boelaert, Yaro, Augustijns, Meda, Schneider et al., Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1, AIDS
Chiu, Chan, Chu, Kwan, Guan et al., Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China, Clin. Infect. Dis
Choi, Lee, Kim, Eun, Kim et al., The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005, Clin. Infect. Dis
Essien, Afamefuna, Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication, Clin. Chem
Fouchier, Hartwig, Bestebroer, Niemeyer, Jong et al., A previously undescribed coronavirus associated with respiratory disease in humans, Proc. Natl. Acad. Sci
Gorbalenya, Snijder, Spaan, Severe acute respiratory syndrome coronavirus phylogeny: toward consensus, J. Virol
Jacomy, Talbot, Susceptibility of murine CNS to OC43 infection, Adv. Exp. Med. Biol
Jacomy, Talbot, Vacuolating encephalitis in mice infected by human coronavirus OC43, Virology
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun
Kono, Tatsumi, Imai, Saito, Kuriyama et al., Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK, Antivir. Res
Kouroumalis, Koskinas, Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report, Ann. Acad. Med. Singapore
Ksiazek, Erdman, Goldsmith, Zaki, Peret et al., A novel coronavirus associated with severe acute respiratory syndrome, N. Engl. J. Med
Lai, Holmes, Coronaviridae: the viruses and their replication
Larson, Reed, Tyrrell, Isolation of rhinoviruses and coronaviruses from 38 colds in adults, J. Med. Virol
Lau, Woo, Yip, Tse, Tsoi et al., Coronavirus HKU1 and other coronavirus infections in Hong Kong, J. Clin. Microbiol
Pardridge, Yang, Diagne, Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes, Immunol. Lett
Rubin, Bernstein, Zvaifler, Studies on the pharmacology of chloroquine. Recommendations for the treatment of chloroquine retinopathy, Arch. Ophthalmol
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect. Dis
Savarino, Gennero, Sperber, Boelaert, The anti-HIV-1 activity of chloroquine, J. Clin. Virol
Singh, Sidhu, Friedman, Maheshwari, Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine, J. Interferon Cytokine Res
Tsai, Nara, Kung, Oroszlan, Inhibition of human immunodeficiency virus infectivity by chloroquine, AIDS Res. Hum. Retrovir
Van Der Hoek, Pyrc, Jebbink, Vermeulen-Oost, Berkhout et al., Identification of a new human coronavirus, Nat. Med
Vijgen, Keyaerts, Lemey, Maes, Van Reeth et al., Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43, J. Virol
Vijgen, Keyaerts, Lemey, Moes, Li et al., Circulation of genetically distinct contemporary human coronavirus OC43 strains, Virology
Vijgen, Keyaerts, Moes, Maes, Duson et al., Development of one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses OC43 and 229E, J. Clin. Microbiol
Vijgen, Keyaerts, Moes, Thoelen, Wollants et al., Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event, J. Virol
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J
Woo, Lau, Chu, Chan, Tsoi et al., Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia, J. Virol
Woo, Lau, Tsoi, Huang, Poon et al., Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia, J. Infect. Dis
DOI record:
{
"DOI": "10.1128/aac.01509-08",
"ISSN": [
"0066-4804",
"1098-6596"
],
"URL": "http://dx.doi.org/10.1128/AAC.01509-08",
"abstract": "<jats:title>ABSTRACT</jats:title>\n <jats:p>Until recently, human coronaviruses (HCoVs), such as HCoV strain OC43 (HCoV-OC43), were mainly known to cause 15 to 30% of mild upper respiratory tract infections. In recent years, the identification of new HCoVs, including severe acute respiratory syndrome coronavirus, revealed that HCoVs can be highly pathogenic and can cause more severe upper and lower respiratory tract infections, including bronchiolitis and pneumonia. To date, no specific antiviral drugs to prevent or treat HCoV infections are available. We demonstrate that chloroquine, a widely used drug with well-known antimalarial effects, inhibits HCoV-OC43 replication in HRT-18 cells, with a 50% effective concentration (± standard deviation) of 0.306 ± 0.0091 μM and a 50% cytotoxic concentration (± standard deviation) of 419 ± 192.5 μM, resulting in a selectivity index of 1,369. Further, we investigated whether chloroquine could prevent HCoV-OC43-induced death in newborn mice. Our results show that a lethal HCoV-OC43 infection in newborn C57BL/6 mice can be treated with chloroquine acquired transplacentally or via maternal milk. The highest survival rate (98.6%) of the pups was found when mother mice were treated daily with a concentration of 15 mg of chloroquine per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg/kg chloroquine and 13% survival when treated with 1 mg/kg chloroquine. Our results show that chloroquine can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.</jats:p>",
"alternative-id": [
"10.1128/AAC.01509-08"
],
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2008-11-12"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 1,
"value": "2009-04-09"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 2,
"value": "2009-08-01"
}
],
"author": [
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Keyaerts",
"given": "Els",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Li",
"given": "Sandra",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Vijgen",
"given": "Leen",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Rysman",
"given": "Evelien",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Verbeeck",
"given": "Jannick",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Van Ranst",
"given": "Marc",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"
}
],
"family": "Maes",
"given": "Piet",
"sequence": "additional"
}
],
"container-title": "Antimicrobial Agents and Chemotherapy",
"container-title-short": "Antimicrob Agents Chemother",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"journals.asm.org"
]
},
"created": {
"date-parts": [
[
2009,
6,
9
]
],
"date-time": "2009-06-09T01:49:59Z",
"timestamp": 1244512199000
},
"deposited": {
"date-parts": [
[
2022,
2,
21
]
],
"date-time": "2022-02-21T20:17:53Z",
"timestamp": 1645474673000
},
"indexed": {
"date-parts": [
[
2024,
5,
14
]
],
"date-time": "2024-05-14T12:35:38Z",
"timestamp": 1715690138699
},
"is-referenced-by-count": 226,
"issue": "8",
"issued": {
"date-parts": [
[
2009,
8
]
]
},
"journal-issue": {
"issue": "8",
"published-print": {
"date-parts": [
[
2009,
8
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://journals.asm.org/non-commercial-tdm-license",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2009,
8,
1
]
],
"date-time": "2009-08-01T00:00:00Z",
"timestamp": 1249084800000
}
}
],
"link": [
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/AAC.01509-08",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/AAC.01509-08",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "235",
"original-title": [],
"page": "3416-3421",
"prefix": "10.1128",
"published": {
"date-parts": [
[
2009,
8
]
]
},
"published-print": {
"date-parts": [
[
2009,
8
]
]
},
"publisher": "American Society for Microbiology",
"reference": [
{
"DOI": "10.1097/00007691-198802000-00004",
"doi-asserted-by": "crossref",
"first-page": "147",
"journal-title": "Ther. Drug Monit.",
"key": "e_1_3_2_2_2",
"unstructured": "Akintonwa, A., S. A. Gbajumo, and A. F. Mabadeje. 1988. Placental and milk transfer of chloroquine in humans. Ther. Drug Monit.10:147-149.",
"volume": "10",
"year": "1988"
},
{
"first-page": "443",
"journal-title": "Res. Commun. Chem. Pathol. Pharmacol.",
"key": "e_1_3_2_3_2",
"unstructured": "Akintonwa, A., M. C. Meyer, and M. K. Yau. 1983. Placental transfer of chloroquine in pregnant rabbits. Res. Commun. Chem. Pathol. Pharmacol.40:443-455.",
"volume": "40",
"year": "1983"
},
{
"DOI": "10.1128/JVI.74.19.8913-8921.2000",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_4_2"
},
{
"DOI": "10.1002/jmv.20288",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_5_2"
},
{
"DOI": "10.1159/000457522",
"doi-asserted-by": "crossref",
"first-page": "191",
"journal-title": "Dev. Pharmacol. Ther.",
"key": "e_1_3_2_6_2",
"unstructured": "Augustijns, P., H. W. Jongsma, and N. Verbeke. 1991. Transplacental distribution of chloroquine in sheep. Dev. Pharmacol. Ther.17:191-199.",
"volume": "17",
"year": "1991"
},
{
"DOI": "10.1177/095632020601700505",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_7_2"
},
{
"first-page": "193",
"journal-title": "The nidoviruses, coronaviruses and arteriviruses",
"key": "e_1_3_2_8_2",
"unstructured": "Blau, D., and K. V. Holmes. 2001. Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway, p. 193-197. In E. Lavi (ed.), The nidoviruses, coronaviruses and arteriviruses. Kluwer, New York, NY.",
"year": "2001"
},
{
"DOI": "10.1097/00002030-200111090-00024",
"doi-asserted-by": "crossref",
"first-page": "2205",
"journal-title": "AIDS",
"key": "e_1_3_2_9_2",
"unstructured": "Boelaert, J. R., S. Yaro, P. Augustijns, N. Meda, Y. J. Schneider, D. Schols, R. Mols, E. A. De Laere, and P. Van de Perre. 2001. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS15:2205-2207.",
"volume": "15",
"year": "2001"
},
{
"DOI": "10.1086/430301",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_10_2"
},
{
"DOI": "10.1086/506350",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_11_2"
},
{
"DOI": "10.1093/clinchem/28.5.1148",
"doi-asserted-by": "crossref",
"first-page": "1148",
"journal-title": "Clin. Chem.",
"key": "e_1_3_2_12_2",
"unstructured": "Essien, E. E., and G. C. Afamefuna. 1982. Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication. Clin. Chem.28:1148-1152.",
"volume": "28",
"year": "1982"
},
{
"DOI": "10.1073/pnas.0400762101",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_13_2"
},
{
"DOI": "10.1128/JVI.78.15.7863-7866.2004",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_14_2"
},
{
"DOI": "10.1007/978-1-4615-1325-4_16",
"doi-asserted-by": "crossref",
"first-page": "101",
"journal-title": "Adv. Exp. Med. Biol.",
"key": "e_1_3_2_15_2",
"unstructured": "Jacomy, H., and P. J. Talbot. 2001. Susceptibility of murine CNS to OC43 infection. Adv. Exp. Med. Biol.494:101-107.",
"volume": "494",
"year": "2001"
},
{
"DOI": "10.1016/S0042-6822(03)00323-4",
"doi-asserted-by": "crossref",
"first-page": "20",
"journal-title": "Virology",
"key": "e_1_3_2_16_2",
"unstructured": "Jacomy, H., and P. J. Talbot. 2003. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology315:20-33.",
"volume": "315",
"year": "2003"
},
{
"DOI": "10.1016/j.bbrc.2004.08.085",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_17_2"
},
{
"DOI": "10.1016/j.antiviral.2007.10.011",
"doi-asserted-by": "crossref",
"first-page": "150",
"journal-title": "Antivir. Res.",
"key": "e_1_3_2_18_2",
"unstructured": "Kono, M., K. Tatsumi, A. M. Imai, K. Saito, T. Kuriyama, and H. Shirasawa. 2008. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir. Res.77:150-152.",
"volume": "77",
"year": "2008"
},
{
"first-page": "149",
"journal-title": "Ann. Acad. Med. Singapore",
"key": "e_1_3_2_19_2",
"unstructured": "Kouroumalis, E. A., and J. Koskinas. 1986. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann. Acad. Med. Singapore15:149-152.",
"volume": "15",
"year": "1986"
},
{
"DOI": "10.1056/NEJMoa030781",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_20_2"
},
{
"first-page": "1163",
"journal-title": "Fields virology",
"key": "e_1_3_2_21_2",
"unstructured": "Lai, M. M. C., and K. V. Holmes. 2001. Coronaviridae: the viruses and their replication, p. 1163-1185. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA.",
"year": "2001"
},
{
"DOI": "10.1002/jmv.1890050306",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_22_2"
},
{
"DOI": "10.1128/JCM.02614-05",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_23_2"
},
{
"DOI": "10.1016/S0165-2478(98)00096-0",
"doi-asserted-by": "crossref",
"first-page": "45",
"journal-title": "Immunol. Lett.",
"key": "e_1_3_2_24_2",
"unstructured": "Pardridge, W. M., J. Yang, and A. Diagne. 1998. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol. Lett.64:45-47.",
"volume": "64",
"year": "1998"
},
{
"first-page": "474",
"journal-title": "Recommendations for the treatment of chloroquine retinopathy. Arch. Ophthalmol.",
"key": "e_1_3_2_25_2",
"unstructured": "Rubin, M., H. N. Bernstein, and N. J. Zvaifler. 1963. Studies on the pharmacology of chloroquine. Recommendations for the treatment of chloroquine retinopathy. Arch. Ophthalmol.70:474-481.",
"volume": "70",
"year": "1963"
},
{
"DOI": "10.1016/S1473-3099(03)00806-5",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_26_2"
},
{
"DOI": "10.1016/S1386-6532(00)00139-6",
"doi-asserted-by": "crossref",
"first-page": "131",
"journal-title": "J. Clin. Virol.",
"key": "e_1_3_2_27_2",
"unstructured": "Savarino, A., L. Gennero, K. Sperber, and J. R. Boelaert. 2001. The anti-HIV-1 activity of chloroquine. J. Clin. Virol.20:131-135.",
"volume": "20",
"year": "2001"
},
{
"DOI": "10.1089/jir.1996.16.725",
"doi-asserted-by": "crossref",
"first-page": "725",
"journal-title": "J. Interferon Cytokine Res.",
"key": "e_1_3_2_28_2",
"unstructured": "Singh, A. K., G. S. Sidhu, R. M. Friedman, and R. K. Maheshwari. 1996. Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine. J. Interferon Cytokine Res.16:725-731.",
"volume": "16",
"year": "1996"
},
{
"DOI": "10.1089/aid.1990.6.481",
"doi-asserted-by": "crossref",
"first-page": "481",
"journal-title": "AIDS Res. Hum. Retrovir.",
"key": "e_1_3_2_29_2",
"unstructured": "Tsai, W. P., P. L. Nara, H. F. Kung, and S. Oroszlan. 1990. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res. Hum. Retrovir.6:481-489.",
"volume": "6",
"year": "1990"
},
{
"DOI": "10.1038/nm1024",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_30_2"
},
{
"DOI": "10.1128/JVI.02675-05",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_31_2"
},
{
"DOI": "10.1016/j.virol.2005.04.010",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_32_2"
},
{
"DOI": "10.1128/JCM.43.11.5452-5456.2005",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_33_2"
},
{
"DOI": "10.1128/JVI.79.3.1595-1604.2005",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_34_2"
},
{
"DOI": "10.1186/1743-422X-2-69",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_35_2"
},
{
"DOI": "10.1128/JVI.79.2.884-895.2005",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_36_2"
},
{
"DOI": "10.1086/497151",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_37_2"
}
],
"reference-count": 36,
"references-count": 36,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.asm.org/doi/10.1128/AAC.01509-08"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1128/asmj-crossmark-policy-page",
"volume": "53"
}